Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
$1.25
-3.1%
$1.23
$1.05
$10.16
$39.19M1.64268,115 shs148,591 shs
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$3.00
+3.6%
$2.23
$1.50
$3.00
$38.96M0.838,193 shs620 shs
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$1.03
$1.01
$0.32
$1.57
$211.41M2.151.93 million shsN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
0.00%+7.92%-4.07%-6.83%-81.68%
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
0.00%+3.45%+33.33%+62.16%-45.45%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
2.3313 of 5 stars
3.52.00.00.01.12.50.6
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.5219 of 5 stars
0.00.00.04.70.60.00.6
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
3.00
Buy$17.711,317.14% Upside
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
0.00
N/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00
N/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EGRX, ZIOP, SPPI, and ACRV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/15/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.00
5/5/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$6.00
5/4/2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/A$5.68 per shareN/A
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$257.55M0.15$7.50 per share0.40N/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$10.11M20.91N/AN/A$0.15 per share6.87
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$80.56M-$2.22N/AN/AN/AN/A-44.66%-40.94%8/12/2025 (Estimated)
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$35.64MN/A0.00N/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest EGRX, ZIOP, SPPI, and ACRV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
-$0.57-$0.51+$0.06-$0.51N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/AN/AN/AN/AN/A
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/AN/AN/AN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
N/A
11.17
11.17
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/A
2.71
2.38
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Institutional Ownership

CompanyInstitutional Ownership
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
71.62%
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
85.36%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
21.67%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
51.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acrivon Therapeutics, Inc. stock logo
ACRV
Acrivon Therapeutics
5831.35 million28.69 millionNot Optionable
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
10012.99 million9.23 millionNo Data
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
86205.25 million199.70 millionOptionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

Recent News About These Companies

Best Global Universities for Oncology
FDA fast-tracks Merck's cancer blockbuster-in-waiting
Childhood Cancers
Alx Oncology Holdings (ALXO)
Pediatric Hematology-Oncology Fellowship
CG Oncology Inc
Immuno-Oncology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
Association of Community Cancer Centers
Oncology News and Research
WBSPH 2024 - Oncology
Kris on Oncology
Oncology Cases & Quizzes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acrivon Therapeutics stock logo

Acrivon Therapeutics NASDAQ:ACRV

$1.25 -0.04 (-3.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 0.00 (0.00%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Eagle Pharmaceuticals stock logo

Eagle Pharmaceuticals NASDAQ:EGRX

$3.00 +0.11 (+3.63%)
As of 07/3/2025 09:30 AM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Spectrum Pharmaceuticals stock logo

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

ZIOPHARM Oncology stock logo

ZIOPHARM Oncology NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.